Martina Garau

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Adrian Towse, Martina Garau, Louis Garrison, 2012, Personalized medicine.

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.

Alec Morton, Praveen Thokala, Michele Tringali, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

Alastair Gray, Adrian Towse, Martina Garau, 2007 .

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

Patricia Cubi-Molla, Martina Garau, Maria Errea, 2020 .

Using MCDA as a Decision Aid in Health Technology Appraisal for Coverage Decisions: Opportunities, Challenges and Unresolved Questions

Martina Garau, N. Devlin, Nancy Devlin, 2017 .

A pilot study of multicriteria decision analysis for valuing orphan medicines.

Jon Sussex, Martina Garau, Alastair Kent, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Martina Garau, Nancy Devlin, Grace Hampson, 2017, PharmacoEconomics - Open.

Medical Research: What's It Worth? Estimating the Economic Benefits from Medical Research in the UK

Stephen Hanney, Edward Nason, Steven Wooding, 2009 .

Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study

Martina Garau, A. Miners, A. Fischer, 2004, BMJ : British Medical Journal.

Multi-Criteria Decision Analysis to Value Orphan Medicines

Jon Sussex, Martina Garau, Alastair Kent, 2013 .

Exploring the Interdependencies of Research Funders in the UK

Daniele Rotolo, Chris Farrell, Jon Sussex, 2014 .